Second-quarter catalysts for the smaller players
Key catalysts approach for Orphazyme, Gemini and Immutep.
Translate’s investment case shifts fully to Covid-19
The company’s lead cystic fibrosis asset fails, shifting the focus to the Sanofi-partnered Covid-19 vaccine.
Kinaset takes a sledgehammer to an asthma conundrum
The nascent company hopes to prove that its inhaled pan-Jak is best in class.
Source flop raises tezepelumab questions
Astrazeneca and Amgen hope the “totality of the data” will win out for their asthma project.
First-quarter catalysts for the smaller players
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Galapagos “win” highlights crowded idiopathic pulmonary fibrosis pipeline
Galapagos is betting big in IPF but others, including Fibrogen and Roche, are also taking aim at the lung disease.
